Titre :

Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.

Auteur(s) :

Fumery, Mathurin [Auteur]
CHU Amiens-Picardie
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Tilmant, Marion [Auteur]
CHU Amiens-Picardie
Yzet, Clara [Auteur]
CHU Amiens-Picardie
Brazier, Franck [Auteur]
CHU Amiens-Picardie
Loreau, Julien [Auteur]
CHU Amiens-Picardie
Turpin, Justine [Auteur]
CHU Amiens-Picardie
Le Mouel, Jean Philippe [Auteur]
CHU Amiens-Picardie
Goeb, Vincent [Auteur]
CHU Amiens-Picardie
Nguyen-Khan, Eric [Auteur]
CHU Amiens-Picardie
Singh, Siddharth [Auteur]
University of California [San Diego] [UC San Diego]
Dupas, Jean-Louis [Auteur]
CHU Amiens-Picardie
Diouf, Momar [Auteur]
CHU Amiens-Picardie

Titre de la revue :

Digestive and Liver Disease

Nom court de la revue :

Dig Liver Dis

Numéro :

51

Pagination :

P484-488

Date de publication :

2018-12-13

ISSN :

1878-3562

Mot(s)-clé(s) en anglais :

Infliximab
IMIDs
Inflammatory bowel disease premedications

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Up to 25% of patients treated with infliximab experience hypersensitivity reactions. Prophylactic premedication prior to infliximab infusion, comprising corticosteroids and/or antihistamines, is widely used in clinical ...
Lire la suite >Up to 25% of patients treated with infliximab experience hypersensitivity reactions. Prophylactic premedication prior to infliximab infusion, comprising corticosteroids and/or antihistamines, is widely used in clinical practice but its efficacy has recently been called into question due to the lack of pathophysiological rationale and validation by controlled trials. We conducted a comprehensive literature search of multiple electronic databases from inception to June 2017 to identify studies reporting the impact of corticosteroid and/or antihistamine premedication on the risk of acute (<24 h) hypersensitivity reaction to infliximab in immune-mediated inflammatory diseases (IMIDs). Random-effects meta-analysis was performed. Ten studies, eight observational studies and two randomized control trials, were identified including a total of 3892 patients with IMIDs, and 1,385 patients with IBD. Corticosteroid premedication was not associated with a decreased risk of hypersensitivity reaction in either IMIDs (7 studies; OR, 1.07, 95%CI, 0.64-1.78; I  = 57.5%) or IBD (3 studies; OR, 1.04, 95% CI, 0.52-2.07; I  = 57%). Antihistamine premedication was not associated with a decreased risk of hypersensitivity reaction in IMIDs (3 studies: OR, 1.39, 95% CI, 0.70-2.73; I  = 85%). The combination of corticosteroids and antihistamines did not decrease the risk of acute infliximab infusion reaction in IMIDs (6 studies; OR, 2.12, 95% CI, 0.61-7.35; I  = 94%), but was associated with an increased risk in IBD (4 studies, OR, 4.17, 95% CI, 1.61-10.78; I  = 77%). Corticosteroid and/or antihistamine premedication is not associated with a decreased risk of acute hypersensitivity reactions to infliximab in patients with IMIDs. We believe that these premedications should no longer be part of standard protocols.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2019-10-22T07:44:15Z
2024-01-23T08:42:39Z